CD274 and nasopharyngeal carcinoma: Recent studies have shown that PD-1/PD-L1 inhibitors provide meaningful clinical benefits in recurrent or metastatic NPC, and ongoing trials are exploring their role in combination with chemoradiotherapy in locally advanced disease (25, 26).